EXACT Therapeutics

Less than 1K followers

EXTX

Euronext Growth Oslo

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

EXACT Therapeutics operates in the medical technology sector. The company specializes in the development of medical devices. The product portfolio is broad and includes, for example, technical platforms for drug testing. In addition to the main business, related ancillary services and value-added products are also offered. The business is operated globally with the largest presence in the Nordic market. The company was previously known as Phoenix Solutions and is headquartered in Oslo.

Market cap

-

Turnover

-

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

All

Press releases

ShowingAll content types

Regulatory press release11/25/2025, 11:57 AM

EXTX: EXACT Therapeutics to present company update

EXACT Therapeutics

Regulatory press release11/24/2025, 7:25 AM

EXACT Therapeutics AS: New option program and receipt of share options by primary insiders

EXACT Therapeutics

Regulatory press release9/25/2025, 6:00 AM

EXTX: EXACT Therapeutics first half 2025 interim results

EXACT Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release9/18/2025, 6:00 AM

EXTX: EXACT Therapeutics' Phase 2 trial to be presented at the 2025 AACR Special Conference

EXACT Therapeutics

Regulatory press release9/9/2025, 6:00 AM

EXTX: EXACT Therapeutic's Acoustic Cluster Therapy to be presented at the Ninth International Cancer lmmunotherapy Conference

EXACT Therapeutics

Regulatory press release8/12/2025, 6:30 AM

EXTX: EXACT Therapeutics to Present at the European Society for Medical Oncology (ESMO) Congress 2025

EXACT Therapeutics

Regulatory press release8/11/2025, 9:08 AM

EXTX: Financial calendar

EXACT Therapeutics

Regulatory press release7/8/2025, 6:30 AM

EXTX: EXACT Therapeutics announces grant of core patent in the U.S.

EXACT Therapeutics

Regulatory press release6/24/2025, 6:00 AM

EXTX: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer

EXACT Therapeutics

Regulatory press release6/13/2025, 10:09 AM

EXACT Therapeutics AS: Primary insider notification

EXACT Therapeutics

Regulatory press release6/13/2025, 10:05 AM

EXTX: EXACT Therapeutics minutes from Annual General Meeting June 13, 2025

EXACT Therapeutics

Regulatory press release6/4/2025, 7:20 AM

EXACT Therapeutics AS - Information regarding voting at the Annual General Meeting 2025

EXACT Therapeutics

Regulatory press release5/28/2025, 12:53 PM

EXACT Therapeutics AS - Notice of Annual General Meeting 2025

EXACT Therapeutics

Regulatory press release5/20/2025, 6:30 AM

EXTX: EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer

EXACT Therapeutics

Regulatory press release5/14/2025, 6:35 AM

EXTX: EXACT Therapeutics announces grant of key patent covering non-invasive delivery of pharmaceuticals to the brain

EXACT Therapeutics

Regulatory press release5/7/2025, 8:47 AM

EXTX: EXACT Therapeutics announces grant of key patent in Japan

EXACT Therapeutics

Regulatory press release4/9/2025, 7:17 PM

EXACT Therapeutics - 2024 Annual Report

EXACT Therapeutics

Regulatory press release1/28/2025, 7:00 AM

EXTX: EXACT Therapeutics and Cordance Medical Announce Early Encouraging Data in Brain Cancer Mice Model

EXACT Therapeutics

Regulatory press release1/7/2025, 10:58 AM

EXTX: Financial calendar

EXACT Therapeutics

Regulatory press release12/24/2024, 11:52 AM

EXACT Therapeutics AS: Share capital increase registered

EXACT Therapeutics

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.